Continental Advisors’s AstraZeneca AZN Stock Holding History

Continental Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-7,000	Closed	-$500K	–	151
2014 Q3	$500K	Sell	7,000 -10,500	-60%	-$769K	0.11%	128
2014 Q2	$1.3M	Sell	17,500 -32,000	-65%	-$2.31M	0.3%	84
2014 Q1	$3.21M	Buy	49,500 +7,500	+18%	+$484K	0.83%	37
2013 Q4	$2.49M	Buy	+42,000	New	+$2.28M	0.54%	53

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Continental Advisors's AZN Position: Q3 2020 in Review

Continental Advisors sold out of AstraZeneca (AZN) in Q3 2020, closing a stake of 2,165 shares — an estimated $229K sold.

Continental Advisors first reported a position in AZN in Q2 2013 and held it in 29 quarters. The position peaked at $3.5M in Q3 2017. 722 funds tracked by Wall St. Rank hold AZN as of Q3 2020.

Continental Advisors reported no remaining AstraZeneca position as of Q3 2020 after selling out during the quarter.
Continental Advisors sold 2,165 AstraZeneca shares in Q3 2020, an estimated $229K.
Continental Advisors first reported a position in AstraZeneca in Q2 2013 and held it in 29 quarters.
Continental Advisors's AstraZeneca position peaked at $3.5M in Q3 2017.
722 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2020.

Based on Continental Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.